Abstract Objective: To test the hypothesis that lutein, compared to the placebo, would enhance the total antioxidant status (TAS) in the preterm infants. Methods: Infants with gestational age ≤34 weeks were randomly assigned to receive a daily dose of lutein and zeaxanthin (0.5 mg + 0.02 mg/Kg/day) or placebo from the seventh day of life until 40th week of postmenstrual age or until discharge. Results: Seventy-seven preterm infants were randomized (38 in the Lutein group and 39 in the Placebo group) with mean gestational age of 30.4 (±2.3) weeks and the mean birth weight of 1415 (±457) grams. The TAS did not result statistically different between the two groups during all the study period, but a significant linear correlation was evidenced between plasma lutein concentration and TAS (r=0.14, p 0.012) and between plasma zeaxanthin concentration and TAS (r=0.13, p 0.02). Conclusions: Supplementation of preterm infants with orally lutein was ineffective in enhancing biological antioxidant capacity. Further studies need to better understand the bioavailability of lutein in the neonatal period in order to identify any best form of supplementation.

Costa, S., Giannantonio, C., Romagnoli, C., Vento, G., Gervasoni, J., Persichilli, S., Zuppi, C., Cota, F., Effects of lutein supplementation on biological antioxidant status in preterm infants: a randomized clinical trial., <<THE JOURNAL OF MATERNAL-FETAL & NEONATAL MEDICINE>>, 2013; (Marzo): N/A-N/A. [doi:10.3109/14767058.2013.783801] [http://hdl.handle.net/10807/43158]

Effects of lutein supplementation on biological antioxidant status in preterm infants: a randomized clinical trial.

Costa, Simonetta;Giannantonio, Carmen;Romagnoli, Costantino;Vento, Giovanni;Gervasoni, Jacopo;Persichilli, Silvia;Zuppi, Cecilia;Cota, Francesco
2013

Abstract

Abstract Objective: To test the hypothesis that lutein, compared to the placebo, would enhance the total antioxidant status (TAS) in the preterm infants. Methods: Infants with gestational age ≤34 weeks were randomly assigned to receive a daily dose of lutein and zeaxanthin (0.5 mg + 0.02 mg/Kg/day) or placebo from the seventh day of life until 40th week of postmenstrual age or until discharge. Results: Seventy-seven preterm infants were randomized (38 in the Lutein group and 39 in the Placebo group) with mean gestational age of 30.4 (±2.3) weeks and the mean birth weight of 1415 (±457) grams. The TAS did not result statistically different between the two groups during all the study period, but a significant linear correlation was evidenced between plasma lutein concentration and TAS (r=0.14, p 0.012) and between plasma zeaxanthin concentration and TAS (r=0.13, p 0.02). Conclusions: Supplementation of preterm infants with orally lutein was ineffective in enhancing biological antioxidant capacity. Further studies need to better understand the bioavailability of lutein in the neonatal period in order to identify any best form of supplementation.
Inglese
Costa, S., Giannantonio, C., Romagnoli, C., Vento, G., Gervasoni, J., Persichilli, S., Zuppi, C., Cota, F., Effects of lutein supplementation on biological antioxidant status in preterm infants: a randomized clinical trial., <>, 2013; (Marzo): N/A-N/A. [doi:10.3109/14767058.2013.783801] [http://hdl.handle.net/10807/43158]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/10807/43158
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 15
  • ???jsp.display-item.citation.isi??? 15
social impact